Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer


Purpose: To investigate short-term response rate, quality of life and toxicities of mannan peptide combinedwith TP regimen in treating patients with non-small cell lung cancer (NSCLC). Patients and
Methods: Fortyone patients with NSCLC were divided into an experimental group treated with TP regimen combined withmannan peptide (21 patients) and a control group treated with TP alone (20 patients).
Results: Response rateswere 61.9% (13/21) for the experimental and 60% (12/20) for the control group (p>0.05). Regarding toxicity,white blood cell decreased more frequently in the control group (65%, 13/20) than in the experimental group(33.3%, 7/21) (p<0.05); nausea and vomiting also occurred more frequently in the control group (55%, 11/20vs 23.8%, 5/21) (p<0.05). In terms of quality of life, this index was improved by 57.1% (12/21) and 25% (5/20)in experimental and control groups, respectively (p<0.05).
Conclusions: Response rate of TP after combinedwith mannan peptide is mildly increased, while this combination alleviates bone marrow suppression as wellas nausea and vomiting of TP, and improves quality of life when treating patients with NSCLC. However, thisconclusion should be confirmed by randomized clinical trails.